Novavax Earnings Forecast and Market Positioning
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Source: NASDAQ.COM
- Stock Performance: Novavax (NVAX) closed at $9.35, reflecting a 1.16% decline from the previous day, underperforming against the S&P 500's 0.28% drop, indicating market caution regarding its future outlook.
- Earnings Expectations: The upcoming earnings report is forecasted to show an EPS of -$0.36, representing a 158.06% year-over-year decline, with quarterly revenue expected at $50.04 million, down 79.08% from the prior year, highlighting significant challenges for the company.
- Analyst Ratings: Currently, Novavax holds a Zacks Rank of #1 (Strong Buy), and while the consensus EPS projection has remained stagnant over the past 30 days, positive estimate revisions are typically correlated with short-term share price momentum, suggesting a potential rebound in market confidence.
- Industry Ranking: The Medical - Biomedical and Genetics industry, where Novavax operates, ranks 110 in the Zacks Industry Rank, placing it in the top 45% of over 250 industries, indicating relative strength and potential investment opportunities for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVAX
Wall Street analysts forecast NVAX stock price to rise
6 Analyst Rating
3 Buy
0 Hold
3 Sell
Hold
Current: 9.350
Low
6.00
Averages
10.50
High
18.00
Current: 9.350
Low
6.00
Averages
10.50
High
18.00
About NVAX
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novavax Earnings Forecast and Market Positioning
- Stock Performance: Novavax (NVAX) closed at $9.35, reflecting a 1.16% decline from the previous day, underperforming against the S&P 500's 0.28% drop, indicating market caution regarding its future outlook.
- Earnings Expectations: The upcoming earnings report is forecasted to show an EPS of -$0.36, representing a 158.06% year-over-year decline, with quarterly revenue expected at $50.04 million, down 79.08% from the prior year, highlighting significant challenges for the company.
- Analyst Ratings: Currently, Novavax holds a Zacks Rank of #1 (Strong Buy), and while the consensus EPS projection has remained stagnant over the past 30 days, positive estimate revisions are typically correlated with short-term share price momentum, suggesting a potential rebound in market confidence.
- Industry Ranking: The Medical - Biomedical and Genetics industry, where Novavax operates, ranks 110 in the Zacks Industry Rank, placing it in the top 45% of over 250 industries, indicating relative strength and potential investment opportunities for investors.
See More
Shah Capital Critiques Novavax Leadership Amid Shareholder Backing
- Shareholder Opposition: Shah Capital highlighted that at Novavax's annual meeting, while all resolutions passed, approximately 38%-41% of votes against board nominees indicate significant shareholder dissatisfaction with the company's leadership.
- Leadership Trust Crisis: Shah Capital described the voting results as “unprecedented opposition,” reflecting a substantial decline in trust towards CEO John Jacobs and overall company performance among shareholders.
- Call for Change: The hedge fund argues that the voting outcome serves as a wake-up call for Novavax to downsize its board, implement cost-cutting measures, and initiate the repurchase of undervalued shares to enhance governance and financial health.
- Uncertain Future Outlook: Although Novavax secured shareholder backing at the meeting, the criticisms from Shah Capital may influence the company's future strategic decisions, particularly amid intensifying competition in the COVID-19 vaccine market.
See More
Novavax Shares Continue Downward Trend
- Stock Price Decline: Novavax (NVAX) shares fell 2.84% to $8.38 on Tuesday afternoon, continuing a six-session downward trend that reflects market concerns about its future performance.
- Market Performance Comparison: Between June 1 and June 8, Novavax's stock dropped approximately 18%, while the S&P 500 declined only 2.56% during the same period, indicating its relative weakness in the market.
- Analyst Ratings: According to Seeking Alpha's Quantrating system, Novavax holds a 'Hold' rating with a score of 2.58 out of 5, achieving a B+ in profitability but an F in growth, highlighting significant challenges in its growth potential.
- Business Model Transition: Although Novavax is transitioning to a royalty-based business model and generating licensing revenue through its partnership with Sanofi, analysts believe there is limited upside in the seasonal COVID-19 vaccine market, with most near-term catalysts already priced into the shares.
See More
FDA Advisory Panel to Vote on COVID Vaccine Target Variant
- Vaccine Target Variant Discussion: The FDA's advisory panel is set to vote on Thursday regarding whether COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant XFG variant, despite limited data on circulating strains, which could impact vaccine efficacy and public health strategies.
- Sign of Procedural Normalcy: The lack of membership changes in the FDA advisory panel indicates a return to procedural normalcy under Health Secretary Robert F. Kennedy Jr., following a series of vaccine policy upheavals, which may help restore public trust in vaccination efforts.
- Monitoring Data Gaps: Assessing the evolution of COVID-19 has become increasingly challenging due to declines in virologic surveillance, sequencing volumes, and timely data sharing from public health departments, as reflected in the CDC's COVID dashboard, where weekly data is currently unavailable due to low sequencing submissions, potentially delaying vaccine strategy updates.
- Variant Evolution and Vaccine Recommendations: The FDA's briefing documents highlight that since last year, the evolution of COVID variants has continued, with LP.8.1 still recommended, but the emergence of new variants like NB.1.8.1 may necessitate adjustments in targets for vaccine manufacturers to effectively respond to the evolving pandemic landscape.
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
Hantavirus Outbreak Sparks Rally in Biotech Stocks
- Impact Assessment: The recent hantavirus outbreak on a cruise ship has sparked a rally in the biotech sector; however, due to its transmission primarily through contact and a much lower contagion rate compared to COVID-19, the market for hantavirus vaccines may be limited, affecting the long-term profitability of related companies.
- Predicting Winners: Even if the situation worsens, it remains challenging for investors to identify which companies will successfully develop hantavirus vaccines, as historical data shows that even major pharmaceutical firms like Sanofi and Merck failed to dominate the COVID-19 vaccine market, highlighting the complexities of investment risks.
- Return on Investment Risks: Even if investors choose companies that successfully develop vaccines, market-beating returns are not guaranteed; data indicates that companies like Pfizer and Moderna, which excelled during the COVID-19 peak, have underperformed the S&P 500 since then, reflecting market uncertainties.
- Potential Investment Opportunities: Despite challenges, Moderna and Pfizer are still considered attractive vaccine manufacturers; Moderna has been working on a hantavirus vaccine and has a promising pipeline, while Pfizer's replenished pipeline and upcoming pivotal trials make it a stock worth serious consideration for long-term returns.
See More
Novavax Earnings Forecast and Market Positioning
- Stock Performance: Novavax (NVAX) closed at $9.35, reflecting a 1.16% decline from the previous day, underperforming against the S&P 500's 0.28% drop, indicating market caution regarding its future outlook.
- Earnings Expectations: The upcoming earnings report is forecasted to show an EPS of -$0.36, representing a 158.06% year-over-year decline, with quarterly revenue expected at $50.04 million, down 79.08% from the prior year, highlighting significant challenges for the company.
- Analyst Ratings: Currently, Novavax holds a Zacks Rank of #1 (Strong Buy), and while the consensus EPS projection has remained stagnant over the past 30 days, positive estimate revisions are typically correlated with short-term share price momentum, suggesting a potential rebound in market confidence.
- Industry Ranking: The Medical - Biomedical and Genetics industry, where Novavax operates, ranks 110 in the Zacks Industry Rank, placing it in the top 45% of over 250 industries, indicating relative strength and potential investment opportunities for investors.
See More
Shah Capital Critiques Novavax Leadership Amid Shareholder Backing
- Shareholder Opposition: Shah Capital highlighted that at Novavax's annual meeting, while all resolutions passed, approximately 38%-41% of votes against board nominees indicate significant shareholder dissatisfaction with the company's leadership.
- Leadership Trust Crisis: Shah Capital described the voting results as “unprecedented opposition,” reflecting a substantial decline in trust towards CEO John Jacobs and overall company performance among shareholders.
- Call for Change: The hedge fund argues that the voting outcome serves as a wake-up call for Novavax to downsize its board, implement cost-cutting measures, and initiate the repurchase of undervalued shares to enhance governance and financial health.
- Uncertain Future Outlook: Although Novavax secured shareholder backing at the meeting, the criticisms from Shah Capital may influence the company's future strategic decisions, particularly amid intensifying competition in the COVID-19 vaccine market.
See More
Novavax Shares Continue Downward Trend
- Stock Price Decline: Novavax (NVAX) shares fell 2.84% to $8.38 on Tuesday afternoon, continuing a six-session downward trend that reflects market concerns about its future performance.
- Market Performance Comparison: Between June 1 and June 8, Novavax's stock dropped approximately 18%, while the S&P 500 declined only 2.56% during the same period, indicating its relative weakness in the market.
- Analyst Ratings: According to Seeking Alpha's Quantrating system, Novavax holds a 'Hold' rating with a score of 2.58 out of 5, achieving a B+ in profitability but an F in growth, highlighting significant challenges in its growth potential.
- Business Model Transition: Although Novavax is transitioning to a royalty-based business model and generating licensing revenue through its partnership with Sanofi, analysts believe there is limited upside in the seasonal COVID-19 vaccine market, with most near-term catalysts already priced into the shares.
See More
FDA Advisory Panel to Vote on COVID Vaccine Target Variant
- Vaccine Target Variant Discussion: The FDA's advisory panel is set to vote on Thursday regarding whether COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant XFG variant, despite limited data on circulating strains, which could impact vaccine efficacy and public health strategies.
- Sign of Procedural Normalcy: The lack of membership changes in the FDA advisory panel indicates a return to procedural normalcy under Health Secretary Robert F. Kennedy Jr., following a series of vaccine policy upheavals, which may help restore public trust in vaccination efforts.
- Monitoring Data Gaps: Assessing the evolution of COVID-19 has become increasingly challenging due to declines in virologic surveillance, sequencing volumes, and timely data sharing from public health departments, as reflected in the CDC's COVID dashboard, where weekly data is currently unavailable due to low sequencing submissions, potentially delaying vaccine strategy updates.
- Variant Evolution and Vaccine Recommendations: The FDA's briefing documents highlight that since last year, the evolution of COVID variants has continued, with LP.8.1 still recommended, but the emergence of new variants like NB.1.8.1 may necessitate adjustments in targets for vaccine manufacturers to effectively respond to the evolving pandemic landscape.
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
Hantavirus Outbreak Sparks Rally in Biotech Stocks
- Impact Assessment: The recent hantavirus outbreak on a cruise ship has sparked a rally in the biotech sector; however, due to its transmission primarily through contact and a much lower contagion rate compared to COVID-19, the market for hantavirus vaccines may be limited, affecting the long-term profitability of related companies.
- Predicting Winners: Even if the situation worsens, it remains challenging for investors to identify which companies will successfully develop hantavirus vaccines, as historical data shows that even major pharmaceutical firms like Sanofi and Merck failed to dominate the COVID-19 vaccine market, highlighting the complexities of investment risks.
- Return on Investment Risks: Even if investors choose companies that successfully develop vaccines, market-beating returns are not guaranteed; data indicates that companies like Pfizer and Moderna, which excelled during the COVID-19 peak, have underperformed the S&P 500 since then, reflecting market uncertainties.
- Potential Investment Opportunities: Despite challenges, Moderna and Pfizer are still considered attractive vaccine manufacturers; Moderna has been working on a hantavirus vaccine and has a promising pipeline, while Pfizer's replenished pipeline and upcoming pivotal trials make it a stock worth serious consideration for long-term returns.
See More
